NYSE:IQV
IQVIA HOLDINGS INC.
A leading global provider of life sciences data and analytics that empowers healthcare stakeholders with actionable market insights and real-world evidence platforms.
Key Metrics
Investment Thesis
Bull Case
Investors may favor IQVIA due to its dominant market position in life sciences data, which offers pricing power and predictable recurring revenue. The transition to cloud-based analytics and AI-driven insights creates opportunities for margin expansion and new growth vectors. Strong free cash flow generation supports a robust balance sheet capable of funding strategic acquisitions or returning capital.
Bear Case
The company faces headwinds from potential deceleration in pharma R&D spending which directly impacts demand for clinical trial services. High interest expenses of $729M weigh on profitability, and the large retained earnings deficit of $7.42B indicates historical capital intensity or past losses. Valuation multiples may be stretched given the limited scope for rapid top-line acceleration in a mature data market.
About IQVIA HOLDINGS INC.
IQVIA Holdings Inc. is a global life sciences data and analytics company providing critical insights to healthcare professionals, payers, and manufacturers. Serving markets across pharmaceuticals, biotechnology, and medical devices, the firm leverages its proprietary data platform to deliver real-world evidence and commercial intelligence solutions.
Analysis
Management Discussion
Revenue grew to $16.31B in 2025 from $14.98B in 2023, reflecting steady top-line expansion despite a slowdown in net income growth which remained flat at $1.36B. Operating cash flow of $2.65B demonstrates strong liquidity generation, though the company utilized significant financing cash outflows for acquisitions totaling $1.71B and share repurchases of $1.24B.
Industry Overview
The life sciences data and analytics industry is experiencing significant growth driven by the shift toward real-world evidence and digital transformation in healthcare delivery. Market participants are increasingly competing on proprietary data depth, AI capabilities, and seamless integration with existing healthcare workflows. Consolidation trends favor large players who can acquire diverse data sets to offer comprehensive end-to-end solutions.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $14.41B | $14.98B | $15.40B | $16.31B |
| Cost of Revenue | $9.38B | $9.74B | $10.03B | $10.88B |
| Gross Profit | $5.03B | $5.24B | $5.38B | $5.43B |
| Operating Expenses | $3.23B | $3.26B | $3.17B | $3.25B |
| Operating Income | $1.80B | $1.98B | $2.20B | $2.18B |
| G&A | $2.07B | $2.05B | $1.99B | $2.00B |
| Stock-Based Comp | $194.0M | $217.0M | $206.0M | $247.0M |
| D&A | $1.13B | $1.12B | $1.11B | $1.14B |
| Depreciation | $160.0M | $151.0M | $149.0M | $160.0M |
| Amortization | $970.0M | $974.0M | $965.0M | $984.0M |
| Other OpEx | $1.16B | $1.21B | $1.18B | $1.25B |
| Non-Operating Income | $-436.0M | $-518.0M | $-533.0M | $-591.0M |
| Interest Expense | $416.0M | $672.0M | $670.0M | $729.0M |
| Interest Income | $13.0M | $36.0M | $47.0M | $45.0M |
| Pre-Tax Income | $1.36B | $1.46B | $1.67B | $1.59B |
| Income Tax | $260.0M | $101.0M | $301.0M | $252.0M |
| Continuing Ops | $1.10B | $1.36B | $1.37B | $1.34B |
| Discontinued Ops | $-12.0M | $0 | $5.0M | $22.0M |
| Net Income | $1.09B | $1.36B | $1.37B | $1.36B |
| Minority Interest | $0 | $0 | $0 | $1.0M |
| Net to Common | $1.09B | $1.36B | $1.37B | $1.36B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $4.98B | $5.60B | $5.83B | $6.25B |
| Cash & Equivalents | $1.22B | $1.38B | $1.70B | $1.98B |
| Marketable Securities | $93.0M | $120.0M | $141.0M | $161.0M |
| Other Current Assets | $3.67B | $4.10B | $3.99B | $4.11B |
| Long-Term Assets | $20.36B | $21.09B | $21.07B | $23.70B |
| PP&E (Net) | $532.0M | $523.0M | $535.0M | $533.0M |
| Intangibles | $4.82B | $4.84B | $4.50B | $4.96B |
| Goodwill | $13.92B | $14.57B | $14.71B | $16.62B |
| Operating Leases | $331.0M | $296.0M | $238.0M | $290.0M |
| Other LT Assets | $658.0M | $726.0M | $822.0M | $970.0M |
| Total Assets | $25.34B | $26.68B | $26.90B | $29.94B |
| Current Liabilities | $5.58B | $6.49B | $6.96B | $8.34B |
| Current Debt | $152.0M | $718.0M | $1.15B | $1.84B |
| Current Leases | $111.0M | $107.0M | $99.0M | $93.0M |
| Deferred Revenue | $1.80B | $1.80B | $1.78B | $2.12B |
| Taxes Payable | $161.0M | $116.0M | $156.0M | $140.0M |
| Other Current Liab | $686.0M | $896.0M | $830.0M | $1.18B |
| Long-Term Liabilities | $13.99B | $14.08B | $13.88B | $14.98B |
| Long-Term Debt | $12.60B | $12.96B | $12.84B | $13.88B |
| LT Operating Leases | $264.0M | $223.0M | $173.0M | $225.0M |
| Other LT Liab | $1.14B | $900.0M | $864.0M | $867.0M |
| Total Liabilities | $19.57B | $20.57B | $20.83B | $23.31B |
| Shareholders' Equity | $5.76B | $6.11B | $6.07B | $6.63B |
| Paid-In Capital | $10.90B | $11.03B | $11.14B | $11.38B |
| Retained Earnings | $3.33B | $4.69B | $6.07B | $7.42B |
| AOCI | $-727.0M | $-867.0M | $-1.04B | $-943.0M |
| Total L&E | $25.34B | $26.68B | $26.90B | $29.94B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $1.09B | $1.36B | $1.37B | $1.36B |
| Non-Cash Adjustments | $484.0M | $332.0M | $1.59B | $1.57B |
| Working Capital Changes | $685.0M | $459.0M | $-249.0M | $-273.0M |
| Cash from Operations | $2.26B | $2.15B | $2.72B | $2.65B |
| Cash from Investing | $-2.01B | $-1.60B | $-1.44B | $-2.31B |
| Share Buybacks | $1.17B | $992.0M | $1.35B | $1.24B |
| Cash from Financing | $-329.0M | $-382.0M | $-878.0M | $-150.0M |
| FX Effect | $-75.0M | $-4.0M | $-68.0M | $79.0M |
| Net Change in Cash | $-150.0M | $160.0M | $326.0M | $278.0M |
| Beginning Cash | $1.37B | $1.22B | $1.38B | $1.70B |
| Ending Cash | $1.22B | $1.38B | $1.70B | $1.98B |
Frequently Asked Questions
How does IQVIA HOLDINGS INC. make money?
The company operates primarily through two main segments: IQVIA Commercial, which offers data, analytics, and technology services to healthcare organizations for commercial decision-making; and IQVIA Clinical, which provides clinical trial management and operational support services to biopharma companies accelerating drug development.
What are the main risks for IQV?
Regulatory changes regarding data privacy and health information exchange could impact access to critical datasets. High competition from digital health startups and traditional consulting firms threatens market share in the commercial intelligence space. Significant debt levels, including $13.88B in long-term debt, constrain flexibility during interest rate hikes or economic downturns.
What is IQV's competitive advantage?
The firm possesses an unmatched proprietary database containing billions of real-world data points on patient journeys and market dynamics. Its deep integration into the global pharmaceutical supply chain creates high switching costs for enterprise clients relying on its analytics infrastructure. Strong recurring revenue streams from long-term service contracts and software subscriptions provide stable cash flow.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.